- Home
- ANAB vs MNTK Comparison
ANAB vs MNTK Comparison
Compare ANAB & MNTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- MNTK
- Stock Information
- Founded
- ANAB 2005
- MNTK 1980
- Country
- ANAB United States
- MNTK United States
- Employees
- ANAB N/A
- MNTK N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- MNTK Natural Gas Distribution
- Sector
- ANAB Health Care
- MNTK Utilities
- Exchange
- ANAB Nasdaq
- MNTK Nasdaq
- Market Cap
- ANAB 759.5M
- MNTK 622.2M
- IPO Year
- ANAB 2017
- MNTK 2021
- Fundamental
- Price
- ANAB $18.40
- MNTK $2.22
- Analyst Decision
- ANAB Buy
- MNTK Hold
- Analyst Count
- ANAB 10
- MNTK 3
- Target Price
- ANAB $36.38
- MNTK $4.00
- AVG Volume (30 Days)
- ANAB 907.9K
- MNTK 300.4K
- Earning Date
- ANAB 05-08-2025
- MNTK 03-13-2025
- Dividend Yield
- ANAB N/A
- MNTK N/A
- EPS Growth
- ANAB N/A
- MNTK N/A
- EPS
- ANAB N/A
- MNTK 0.07
- Revenue
- ANAB $91,280,000.00
- MNTK $175,736,000.00
- Revenue This Year
- ANAB N/A
- MNTK $38.31
- Revenue Next Year
- ANAB $59.43
- MNTK $14.94
- P/E Ratio
- ANAB N/A
- MNTK $32.45
- Revenue Growth
- ANAB 432.03
- MNTK 0.48
- 52 Week Low
- ANAB $12.21
- MNTK $2.00
- 52 Week High
- ANAB $41.31
- MNTK $6.22
- Technical
- Relative Strength Index (RSI)
- ANAB 55.72
- MNTK 36.15
- Support Level
- ANAB $17.50
- MNTK $2.03
- Resistance Level
- ANAB $19.60
- MNTK $2.27
- Average True Range (ATR)
- ANAB 1.34
- MNTK 0.34
- MACD
- ANAB 0.16
- MNTK 0.05
- Stochastic Oscillator
- ANAB 57.04
- MNTK 23.66
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a United States-based renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments: Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.